CD274 and neoplasm: Our results indicate that our BsAbs have the capability to release PD-1/PD-L1 checkpoint inhibition, to induce EGFR-directed tumor anti-proliferative activity and to maintain Fc-mediated ADCC effector functions to provide more pronounced killing of TNBC tumors, suggesting that the BsAbs targeting EGFR and PD-L1 warrant further investigation as a targeted antibody therapeutic to treat TNBC and tumors expressing EGFR.